SCHEMBL1964633

SCHEMBL1964633

COC(=O)c1c(O)c2cc3cc(F)ccc3n2n(Cc2ccc(F)cc2)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
TP53 P04637 3/20 0.40
F10 P00742 1/20 0.39
HSP90AA1 P07900 2/20 0.39
HSP90B1 P14625 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
PLA2G2A P14555 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 1/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3723620 0.91 KMT2A (0.43) MAPTTP53HSP90AA1HSP90B1NPC1
SCHEMBL3725348 0.84 KDM4E (0.40) MAPTKDM4EPKMTP53HSP90AA1
SCHEMBL1967331 0.84 HSP90AA1 (0.41) MAPTKDM4EPKMTP53HSP90AA1
SCHEMBL3731074 0.82 EGLN3 (0.51) L3MBTL1MEN1KMT2A
SCHEMBL1965300 0.79 P2RX7 (0.42) MAPTKDM4EPKMTP53HSP90AA1
SCHEMBL1969294 0.77 HSP90AA1 (0.41) MAPTKDM4EPKMTP53HSP90AA1
SCHEMBL1964132 0.74 KMT2A (0.45) MAPTKDM4ETP53SMN1; SMN2ALDH1A1
SCHEMBL3727894 0.73 EGLN1 (0.53) L3MBTL1MEN1KMT2A
SCHEMBL1966134 0.73 L3MBTL1 (0.44) KDM4ETP53SMN1; SMN2ALDH1A1HPGD
SCHEMBL1966135 0.73 L3MBTL1 (0.44) KDM4ETP53SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 MAPT 4198/4885KDM4E 471/4885PKM 813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.